AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia

Multiple myeloma, the second most common haematological malignancy in the U.S., is currently incurable. Disruption of the intrinsic apoptotic pathway by BCL2 and MCL1 upregulation is observed in >80% of myeloma cases and is associated with an aggressive clinical course. Remarkably, there is no ap...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Haematol
Main Authors: Paulus, Aneel, Chitta, Kasyapa, Akhtar, Sharoon, Personett, David, Miller, Kena C., Thompson, Kevin J., Carr, Jennifer, Kumar, Shaji, Roy, Vivek, Ansell, Stephen M., Mikhael, Joseph R., Dispenzieri, Angela, Reeder, Craig B., Rivera, Candido E., Foran, James, Chanan-Khan, Asher
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4406280/
https://ncbi.nlm.nih.gov/pubmed/24236538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.12633
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares